SUMMIT THERAPEUTICS INC (SMMT)

Company Profile

Summit Therapeutics, Inc. a biopharmaceutical company, which discovers, develops, and commercializes medicines to treat infectious diseases. The company is headquartered in Menlo Park, California and currently employs 76 full-time employees. The company went IPO on 2004-10-14. The firm is focused on the discovery, development, and commercialization of medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm is engaged in research and development activities, primarily comprising oncology product research activities (including ivonescimab), and anti-infectives program activities. Ivonescimab, is a novel, potential first-in-class bispecific antibody intending to combine the benefits of immunotherapy via a blockade of PD-1 with the anti-angiogenesis benefits of an anti-VEGF into a single molecule. The Company’s preclinical candidate, SMT-738, from the DDS-04 series for development in the fight against multi-drug resistant infections, specifically Carbapenem-resistant Enterobacteriaceae (CRE) infections. The company owns a genetics platform and a suite of software-based technologies (Discuva Platform).

Company Info

SUMMIT THERAPEUTICS INC

2882 Sand Hill Road, Suite 106

Menlo Park CALIFORNIA 02142

P: 16175147149

CEO: Robert W. Duggan

Employees: 76

Website: https://www.smmttx.com/